Merck Charges Jubilant With Infringement Of Januvia Patent
Executive Summary
Merck & Co has sought to block Jubilant Life Sciences over the alleged infringement of its patent on Januvia (sitagliptin) in India, continuing with a string of IPR-related legal action in the country.